Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom.
about
Haemophilus influenzae type b epiglottitis as a cause of acute upper airways obstruction in children.Haemophilus influenzae type b epiglottitis. Occasional cases will present.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Haemophilus influenzae type b conjugate vaccines.Impaired haemophilus influenzae type b transplacental antibody transmission and declining antibody avidity through the first year of life represent potential vulnerabilities for HIV-exposed but -uninfected infants.The UK Hib vaccine experienceImmunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in Southwestern Alaska.Pneumococcal vaccination and revaccination of older adults.Pneumococcal serotype-specific antibodies persist through early childhood after infant immunization: follow-up from a randomized controlled trial.Hib vaccination in infants born prematurely.Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure.Effect of a fourth Haemophilus influenzae type b immunisation in preterm infants who received dexamethasone for chronic lung disease.Naturally acquired and conjugate vaccine-induced antibody to Haemophilus influenzae type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in MaliImmune response to Haemophilus influenzae type b vaccination in patients with chronic renal failure.Haemophilus influenzae type b reemergence after combination immunization.Haemophilus influenzae type b disease and vaccine booster dose deferral, United States, 1998-2009.Acute epiglottitis: epidemiology, clinical presentation, management and outcome.Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates.Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United KingdomQuadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.The seroepidemiology of Haemophilus influenzae type b prior to introduction of an immunization programme in Kathmandu, Nepal.Immunogenicity of Haemophilus influenzae type b protein conjugate vaccines in very low birth weight infants.Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.Modelling the effects of booster dose vaccination schedules and recommendations for public health immunization programs: the case of Haemophilus influenzae serotype b.Invasive Haemophilus influenzae serotype e and f disease, England and Wales.Invasive Haemophilus influenzae type b disease in England and Wales: who is at risk after 2 decades of routine childhood vaccination?Legacy of bacterial meningitis in infancy. Many children continue to suffer functionally important deficits.Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines.Conjugate vaccines.Memory B cell compartment constitution and susceptibility to recurrent lower respiratory tract infections in young children.Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006-2014.Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom.Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody.The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine.
P2860
Q33812810-667DA52D-65D0-45E0-8AD4-508830295B02Q33813738-C0FA5319-50C1-4AD1-B430-63517032F4D2Q34170021-151F7F2D-700F-4A75-80EF-0F835D26EA0DQ34349892-75A519EF-0698-4689-A5A3-C52891DA14B4Q34593078-790755E2-D2D3-4677-91BF-ABE82436F7A9Q34649094-AB2550A0-7AB8-4205-89A5-F4F04AB1512AQ34720237-3A92297C-6AAF-4D3B-86E6-78EEB33E8331Q34926870-6782CD14-E481-4C47-B82F-1EB317DF44FCQ35117891-93875506-6E02-4C96-9932-CB38E9CAEAE8Q35275707-03658E7C-3C03-4657-ACB0-16E4CD544EC1Q35276278-2D751067-1CC7-4BFB-B7F9-A6F6CDCD56FEQ35556412-0E56133D-A72D-40DF-A4CF-54ACD890D9E9Q36005810-B9F063BA-AAB0-4E39-BAB4-A6A29C5805E5Q36017699-F699E708-0198-4057-ADDF-11187B857E64Q36026108-6B3A6A88-F2C8-4321-A58E-F70B78D1B672Q36154778-C803DBD2-D8E2-4A64-B3E7-C969CF41A543Q36950577-233031C2-B73F-44F1-93B4-D54ED661A1D5Q37077660-97DB0A39-DDBC-4088-94B8-E94D34A0380FQ37099250-D68D4E1D-9C40-472D-9FBF-06886AF7E569Q37461347-CE02384E-139C-44C5-8778-5B1EE3074E1FQ37504676-D706D43E-8AF2-4790-866D-F4C7FE1347D0Q37650506-BA29C240-794D-4E45-8688-F2DB55B093A2Q37878485-6ED400AA-36C5-4C31-A2C2-324F76591091Q41106547-236E13DD-AA8A-4D33-A9C1-BF7C058BF59DQ42176219-F885732B-7F81-4D52-B0BE-62FD7A76F9A7Q42265961-0455C1A7-A12E-4F30-97A0-56459CCD6179Q42773679-84FE5A07-60BB-4F51-8B4C-4C0E1CCEDA5EQ42909238-85DA54D3-7798-4616-B068-0663D3931A3CQ43098481-CB892FA9-C6FA-4BF4-B5C6-3DCDC8A967E2Q44220499-0A8479E6-B59F-4836-AFF1-0FB563659AF0Q47663756-56692168-4C74-4D62-9A1E-E0A3FBBEFF85Q51908614-464407DF-502C-4318-9854-1FD73D38D794Q51968253-4369F80F-35E6-42B7-99F7-684203732178Q51978164-5D026CDC-3861-4527-AA40-ACC3DBD59B70
P2860
Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Antibody concentration and cli ...... ination in the United Kingdom.
@en
Antibody concentration and cli ...... ination in the United Kingdom.
@nl
type
label
Antibody concentration and cli ...... ination in the United Kingdom.
@en
Antibody concentration and cli ...... ination in the United Kingdom.
@nl
prefLabel
Antibody concentration and cli ...... ination in the United Kingdom.
@en
Antibody concentration and cli ...... ination in the United Kingdom.
@nl
P2093
P356
P1476
Antibody concentration and cli ...... cination in the United Kingdom
@en
P2093
H Griffiths
H J Azzopardi
J Bowen-Morris
P304
P356
10.1001/JAMA.284.18.2334
P407
P577
2000-11-01T00:00:00Z